Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections

References

• Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin. Infect. Dis.17, S487–S491 (1993).
   PubMed Web of Science ®Google Scholar
• Pannuti C, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer69(11), 2653–2662 (1992).
   PubMedGoogle Scholar
• McNeil MM, Nash SL, Haijeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin. Infect. Dis.33(5), 641–647 (2001).
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA. Emerging fungal diseases. Clin. Infect. Dis.41(4), 521–526 (2005).
   PubMed Web of Science ®Google Scholar
• Richardson MD. Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother.56(Suppl. 1), i5–i11 (2005).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis.37(5), 634–643 (2003).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Torres HA, Chagua M et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand. J. Infect. Dis.36(8), 564–569 (2004).
   PubMed Web of Science ®Google Scholar
• Pinner RW, Teutsch SM, Simonsen L et al. Trends in infectious mortality in the United States. JAMA275(3), 189–193 (1996).
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case–fatality rate: systematic review of the literature. Clin. Infect. Dis.32(3), 358–366 (2001).
   PubMed Web of Science ®Google Scholar
• Rabkin JM, Oroloff SL, Corless CL et al. Association of fungal infection and increased mortality in liver transplant recipients. Am. J. Surg.179, 426–430 (2000).
   PubMedGoogle Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood100, 4358–4366 (2002).
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin. Infect. Dis.39, 588–590 (2004).
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Queiroz-Telles F et al.Fusarium infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.38, 1237–1242 (2004).
   PubMed Web of Science ®Google Scholar
• Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin. Infect. Dis.34, 467–476 (2002).
   PubMed Web of Science ®Google Scholar
• Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr. Opin. Infect. Dis.16(6), 607–612 (2003).
   PubMed Web of Science ®Google Scholar
• Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J. Clin. Microbiol.41(12), 5525–5529 (2003).
   PubMed Web of Science ®Google Scholar
• Procop GW, Roberts GD. Emerging fungal diseases: the importance of the host. Clin. Lab. Med.24(3), 691–719 vi–vii (2004).
   PubMedGoogle Scholar
• Imhof A, Balajee SA, Fredericks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis.39(5), 743–746 (2004).
   PubMed Web of Science ®Google Scholar
• Siwek, GT, Dodgson KJ, Magalhaes-Silverman M et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis.39(4), 584–587 (2004).
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis during voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med.350(9), 950–952 (2004).
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kami M, Murashige N, Kishi Y, Fujisaki G, Mitamura T. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica89(11), ECR 42 (2004).
   Google Scholar
• Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP et al. Infections due to Aspergillus terrreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis.39(2), 192–198 (2004).
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine79(4), 250–260 (2000).
   PubMed Web of Science ®Google Scholar
• Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis.29(6), 1402–1407 (1999).
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis.33(6) 915–916 (2001).
   PubMedGoogle Scholar
• Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl. Infect. Dis.1(4), 272–283 (1999).
   Google Scholar
• Denning DW. Invasive aspergillosis. Clin. Infect. Dis.26(4), 781–803 (1998).
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White Met al. A double blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis.35(4), 359 (2002).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high loading dose regimen with standard dosing (AmBiload Trial). Clin. Infect. Dis.44(10), 1289–1297 (2007).
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother.42, 3018–3021 (1998).
   PubMed Web of Science ®Google Scholar
• Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-104,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother.40, 1948–1949 (1996).
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn. Microbiol. Infect. Dis.31, 297–300 (1998).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilties to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol.39, 3254–3259 (2001).
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother.41, 575–577 (1997).
   PubMed Web of Science ®Google Scholar
• Oakley KL, Moore CB, Denning DW. In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J. Antimicrob. Chemother.42, 91–94 (1998).
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar DH. A comparative study of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH-56592). Antimicrob. Chemother.46, 229–234 (2000).
   Google Scholar
• Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis.17, 573–575 (1998).
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J. Clin. Microbiol.37, 3946–3951 (1999).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiacious fungi. J. Clin. Microbiol.39, 954–958 (2001).
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Ryiz-Diez B, Martinez-Suarez JV, Monzon A, Rodriguez-Tudela JL. Comparative in vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother.43, 149–151 (1999).
   PubMed Web of Science ®Google Scholar
• Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother.45, 2151–2153 (2001).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,456) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol.36, 198–202 (1998).
   PubMed Web of Science ®Google Scholar
• Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomycosis dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother.44, 1734–1736 (2000).
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J. Antimicrob. Chemother.61(Suppl. 1), i19–i30 (2008).
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Carver PL. Update on echinocandins. Semin. Respir. Crit. Care Med.29, 211–219 (2008).
   PubMed Web of Science ®Google Scholar
• Fritz JM, Brielmaier BD, Dubberke ER. Micafungin for the prophylaxis and treatment of Candida infections. Expert Rev. Anti. Infect. Ther.6(2), 153–162 (2008).
   PubMed Web of Science ®Google Scholar
• Sanati H, Belanger P, Fratti B, Ghannoum M. A new triazole voriconazole (UK-109,496) blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob. Agents Chemother.41, 2492–2496 (1997).
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Zhanel GC, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformansisolates from blood cultures of neutropenic patients. Antimicrob. Agents Chemother.43, 1463–1464 (1999).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Zhang J, Messer SA et al.In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother.43, 169–171 (1999).
   PubMed Web of Science ®Google Scholar
• Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole, and voriconazole. J. Antimicrob. Chemother.48, 919–921 (2001).
   PubMedGoogle Scholar
• Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob. Agents Chemother.46, 2546–2553 (2002).
   PubMed Web of Science ®Google Scholar
• Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin. Invest. Drugs11, 409–429 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Mats OK, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single or multiple dose administration. Antimicrob. Agents Chemother.48(6), 2166–2172 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr. Infect. Dis. J.21, 240–248 (2002).
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Blumer JL, Yanovicjh S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin, Pharmacol.42, 395–402 (2002).
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy23, 1441 (2003).
   PubMedGoogle Scholar
• Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis.46(2), 201–211 (2008).
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao X, Shin J, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinetics41(12), 913–958 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36, 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis.34, 563–571 (2002).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347(6), 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Wenzel R, Del Farero A, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J. Antimicrob. Chemother.55, 352–361 (2005).
   PubMed Web of Science ®Google Scholar
• Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am. J. Med.119(6), 527 e17–e24 (2006).
   Google Scholar
• Baden LR, Katz JT, Fishman JA et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation76(11), 1632–1637 (2003).
   PubMed Web of Science ®Google Scholar
• Husain S, Paterson DL, Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant.6(12), 3008–3016 (2006).
   PubMed Web of Science ®Google Scholar
• Camuset J, Nunes H, Dombret MC et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest131(5), 1435–1441 (2007).
   PubMed Web of Science ®Google Scholar
• Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J. Infect.52(5), e133–e137 (2006).
   PubMedGoogle Scholar
• Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med.346, 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever [letter]. N. Engl. J. Med.346, 289–290 (2002).
   PubMed Web of Science ®Google Scholar
• Ullman AJ, Heussel CP, Cornerly OA. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy [letter]. N. Engl. J. Med.346, 1745–1747 (2002).
   Google Scholar
• Walsh TJ, Lee J, Dismukes WE. Decisions about voriconazole versus liposomal amphotericin B [letter]. N. Engl. J. Med.346, 1499 (2002).
   PubMedGoogle Scholar
• Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis.22(11), 651–655 (2003).
   PubMed Web of Science ®Google Scholar
• Kullberg B, Sobel J, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet366(9), 1435–1442 (2005).
   PubMed Web of Science ®Google Scholar
• Ally R, Schurmann D, Kreisel W et al. A randomized, double blind, double dummy multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis.33, 1447–1454 (2001).
   PubMed Web of Science ®Google Scholar
• Hegener P, Troke P, Fatkenheuer G, Diehl V, Ruhnke M. Treament of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS12, 2227–2228 (1998).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Cripper F, Wald A, Corey L. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.34, 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Hollis RA, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol.41(3), 3623–3626 (2003).
   PubMed Web of Science ®Google Scholar
• Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lustar I Voriconazole for the treatment of S. apiospermum and S. prolificans infection. Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America. New Orleans, LA, USA, 7–10 September 2000 (Abstract 305).
   Google Scholar
• Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses46(5–6), 233–236 (2003).
   PubMed Web of Science ®Google Scholar
• Studahl M, Backteman T, Stalhammar F, Chryssanthou E, Petrini B. Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery. Acta Paediatr.92(8), 980–982 (2003).
   PubMed Web of Science ®Google Scholar
• Nesky MA, McDougal EC, Peacock JE Jr. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin. Infect. Dis.31, 673–677 (2000).
   PubMed Web of Science ®Google Scholar
• Munoz P, Marin M, Tornero P et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin. Infect. Dis.31, 1499–1501 (2000).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J. Clin. Microbiol.36, 1436–1438 (1998).
   PubMed Web of Science ®Google Scholar
• Poza G, Montoya J, Redondo C et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin. Infect. Dis.30, 981–982 (2000).
   PubMed Web of Science ®Google Scholar
• Jabado N, Casanova J-L, Haddad E et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin. Infect. Dis.27, 1437–1441 (1998).
   PubMed Web of Science ®Google Scholar
• Hernandez Prats C, Llinares Tello F, Burgos San Jose A, Selva Otaolaurruchi J, Ordovas Baines JP. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann. Pharmacother.38(3), 414–417 (2004).
   PubMed Web of Science ®Google Scholar
• Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br. J. Ophthamol.84, 932–933 (2000).
   PubMed Web of Science ®Google Scholar
• Vincent AL, Cabrero JE, Greene JN et al. Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient. Cancer Control10(5), 414–419 (2003).
   PubMedGoogle Scholar
• Friese G, Discher T, Fussle R, Schmalreck A, Lohmeyer J. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS15, 2344–2345 (2001).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ et al. Voriconazole for less common emerging or refractory fungal infections. Clin. Infect. Dis.36, 1122–1131 (2003).
   PubMed Web of Science ®Google Scholar
• Hillmarsdottir J, Thorsteinsson SB, Asmundsson P et al. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scan. J. Infect. Dis.32, 331–331 (2000).
   PubMedGoogle Scholar
• Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother.50, 1570 (2006).
   PubMed Web of Science ®Google Scholar
• Trifilio S, Ortiz R, Pennich G et al. Voriconazole drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant35, 509 (2005).
   PubMed Web of Science ®Google Scholar
• Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer109(8), 1532–1535 (2007).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother.46, 2564–2568 (2002).
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis; synergistic interaction between antifungal triazole and an echinocandin. J. Infect. Dis187, 1831–1833 (2003).
   PubMedGoogle Scholar
• Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis.39, 797–802 (2004).
   PubMed Web of Science ®Google Scholar
• Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis.44(4), 531–540 (2007).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Hollis RJ et al. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagn. Microbiol. Infect. Dis.63(2), 233–236 (2009).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al.In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol.46(8), 2568–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Verweij PE, Mellado E, Melchers WJG. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med.356(14), 1481–1483 (2007).
   PubMed Web of Science ®Google Scholar
• Tomaszewski K, Purkins L. Visual effects with voriconazole. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16–19 December 2001 (Abstract A639).
   Google Scholar
• Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin. Infect. Dis.47, e7–e10 (2008).
   PubMed Web of Science ®Google Scholar
• Huang DB, Wu JJ, Lahart CJ. Toxic epidermal necrolysis as a complication of treatment with voriconazole. South. Med. J.97(11), 1116–1117 (2004).
   PubMed Web of Science ®Google Scholar
• Curigliano G, Formica V, DePas G et al. Life threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. Ann. Oncol.17, 1174–1175 (2006).
   PubMedGoogle Scholar
• Vishnubhotla P, Ibrahim RB, Abidi MH et al. Fever and eosinophilia associated with voriconazole. Ann. Pharmacother.38, 900 (2004).
   PubMedGoogle Scholar
• Tolland JP, McKeown PP, Corbett JR. Voriconazole-induced pseudoporphyria. Photodermatol. Photoimmunol. Photomed.23(1), 29–31 (2007).
   PubMed Web of Science ®Google Scholar
• Trifilio SM, Bennett CL,Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem cell transplants or intensive chemotherapy. Bone Marrow Transplant.39, 425–429 (2007).
   PubMed Web of Science ®Google Scholar
• Vigouroux S, Morin O, Moreau P et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin. Infect. Dis.40, e35–e37 (2005).
   PubMed Web of Science ®Google Scholar
• Balasubramanian L, Trifilio SM, Tallman M, Mehta J, Bennett C. Breakthrough zygomycoses in patients receiving antifungal therapy with voriconazole. J. Clin. Oncol.23(16S), 6664 (2005).
   PubMedGoogle Scholar
• Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin. Infect. Dis.40(5), 770–771 (2005).
   PubMed Web of Science ®Google Scholar